Skip to main content
← All trials
Recurrent Mycosis Fungoides

What this study is

This study is being done to assess mogamulizumab-associated rash in patients diagnosed with mycosis fungoides or sezary syndrome and treated with standard of care mogamulizumab. One of the most common side effects of mogamulizumab is a rash, currently named mogamulizumab-associated rash (MAR) which can look like MF or SS. However, mogamulizumab-associated rash (MAR) does not indicate failure of mogamulizumab, and may be a sign that the drug is working. If not properly evaluated, mogamulizumab-associated rash (MAR) could be misinterpreted as worsening of mycosis fungoides/sezary syndrome, which could lead doctors to recommend stopping mogamulizumab treatment early. The information learned by doing this research study may help tell the difference between mogamulizumab-associated rash (MAR) (sometimes also called "drug eruption") and worsening of the disease. It may also help to uncover information about the cause of mogamulizumab-associated rash (MAR).

What's being tested

  • Non-Interventional Study

    Intervention · OTHER

    Non-interventional study

Study details

Official title
A Prospective, US-Based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed With Mycosis Fungoides or Sézary Syndrome and Treated With Standard of Care Mogamulizumab
Sponsor
City of Hope Medical Center
Conditions
Recurrent Mycosis Fungoides · Recurrent Sezary Syndrome · Refractory Mycosis Fungoides · Refractory Sezary Syndrome · Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8 · Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Enrolling
100 people
Starts
2024-12-06
Est. completion
2027-01-12
Record
View on ClinicalTrials.gov ↗